GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (OTCPK:IPSEY) » Definitions » Capex-to-Revenue

Ipsen (IPSEY) Capex-to-Revenue : 0.07 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Ipsen Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Ipsen's Capital Expenditure for the six months ended in Dec. 2023 was $-119.85 Mil. Its Revenue for the six months ended in Dec. 2023 was $1,835.66 Mil.

Hence, Ipsen's Capex-to-Revenue for the six months ended in Dec. 2023 was 0.07.

Ipsen Capex-to-Revenue Historical Data

The historical data trend for Ipsen's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipsen Capex-to-Revenue Chart

Ipsen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.05 0.15 0.08 0.06

Ipsen Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.08 0.08 0.05 0.07

Competitive Comparison of Ipsen's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Ipsen's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ipsen's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipsen's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ipsen's Capex-to-Revenue falls into.


Ipsen Capex-to-Revenue Calculation

Ipsen's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-199.455) / 3605.671
=0.06

Ipsen's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-119.847) / 1835.66
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ipsen  (OTCPK:IPSEY) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Ipsen Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ipsen's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Ipsen (IPSEY) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (OTCPK:IPSEY) » Definitions » Capex-to-Revenue
Comparable Companies
XPAR:VETO XPAR:BOI XPAR:EAPI XPAR:AB XPAR:MLCOT XPAR:ALRPD ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX HKSE:03692 TSE:4507 NSE:DIVISLAB BOM:500124
Traded in Other Exchanges
IPSEF:USA 0MH6:UK IPN:France I7G:Germany
Address
65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100
Website
https://www.ipsen.com
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.